SG11201805052YA - Therapeutic methods using erythrocytes - Google Patents

Therapeutic methods using erythrocytes

Info

Publication number
SG11201805052YA
SG11201805052YA SG11201805052YA SG11201805052YA SG11201805052YA SG 11201805052Y A SG11201805052Y A SG 11201805052YA SG 11201805052Y A SG11201805052Y A SG 11201805052YA SG 11201805052Y A SG11201805052Y A SG 11201805052YA SG 11201805052Y A SG11201805052Y A SG 11201805052YA
Authority
SG
Singapore
Prior art keywords
international
nsw
red blood
blood cells
street
Prior art date
Application number
SG11201805052YA
Other languages
English (en)
Inventor
Elisabeth Karsten
Ben Herbert
Alan Liddle
Cameron Hill
Original Assignee
Sangui Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905309A external-priority patent/AU2015905309A0/en
Application filed by Sangui Bio Pty Ltd filed Critical Sangui Bio Pty Ltd
Publication of SG11201805052YA publication Critical patent/SG11201805052YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/25—Urinary tract cells, renal cells
    • C12N2502/256—Renal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201805052YA 2015-12-22 2016-12-22 Therapeutic methods using erythrocytes SG11201805052YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015905309A AU2015905309A0 (en) 2015-12-22 Therapeutic methods using erythrocytes
PCT/AU2016/000404 WO2017106899A2 (fr) 2015-12-22 2016-12-22 Méthodes thérapeutiques utilisant les érythrocytes

Publications (1)

Publication Number Publication Date
SG11201805052YA true SG11201805052YA (en) 2018-07-30

Family

ID=59088638

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805052YA SG11201805052YA (en) 2015-12-22 2016-12-22 Therapeutic methods using erythrocytes

Country Status (9)

Country Link
US (1) US11564948B2 (fr)
EP (1) EP3393482A4 (fr)
JP (2) JP2018538343A (fr)
KR (1) KR20180102096A (fr)
CN (1) CN108883133A (fr)
AU (1) AU2016374643B2 (fr)
CA (1) CA3009369A1 (fr)
SG (1) SG11201805052YA (fr)
WO (1) WO2017106899A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2768942T (lt) 2011-10-17 2020-04-10 Massachusetts Institute Of Technology Pristatymas į ląstelės vidų
SG11201601927SA (en) 2013-08-16 2016-04-28 Massachusetts Inst Technology Selective delivery of material to cells
SG11201703044PA (en) 2014-10-31 2017-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
EP3218492A4 (fr) 2014-11-14 2018-10-10 Massachusetts Institute Of Technology Acheminement de composés et de compositions dans des cellules activé par des perturbations et un champ
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
CA2988996A1 (fr) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Administration de substances a des cellules anucleees
WO2017041051A1 (fr) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Administration intracellulaire de biomolécules à des cellules comprenant une paroi cellulaire
CN108700565B (zh) 2015-10-07 2021-10-29 善威生物私人有限公司 血液制备和图谱分析
CN110366597B (zh) * 2016-12-20 2024-03-29 善威生物私人有限公司 用蛋白酶抑制剂进行血液图谱分析
WO2022192434A1 (fr) * 2021-03-10 2022-09-15 Terasaki Institute For Biomedical Innovation Procédés et systèmes de préparation de viande cultivée à partir de sang ou d'une biomasse cellulaire

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
FR2778851B1 (fr) * 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
US8431117B2 (en) 1999-08-30 2013-04-30 David S Terman Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
WO2002007752A2 (fr) * 2000-07-24 2002-01-31 Gendel Limited Diffusion ii-2 d'un polypeptide
PT1495328E (pt) 2002-04-16 2014-09-09 Vlaams Interuniv Inst Biotech Um marcador para medir cirrose hepática
GB0325483D0 (en) 2003-10-31 2003-12-03 Plasmacute As Assay
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7378054B2 (en) 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
US20060166223A1 (en) 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
EP1875248A2 (fr) 2005-03-29 2008-01-09 Inverness Medical Switzerland GmbH Dispositif et procede de surveillance d'un patient
WO2008134526A2 (fr) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Profilage de glycoprotéines du cancer de la vessie
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
WO2009111595A2 (fr) 2008-03-04 2009-09-11 Ridge Diagnostics, Inc. Diagnostic et surveillance de troubles dépressifs basés sur une pluralité de panels de biomarqueurs
KR20190000928A (ko) * 2008-05-06 2019-01-03 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
WO2010147621A1 (fr) 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Procédés d'amélioration des effets indésirables associés à la transfusion de globules rouges âgés
EP2464966A1 (fr) 2009-08-13 2012-06-20 Basf Se Moyens et procédés pour diagnostiquer des désordres de la thyroïde
US20130202625A1 (en) * 2010-01-21 2013-08-08 The Regents Of The University Of Californa Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2011127056A2 (fr) 2010-04-05 2011-10-13 The Uab Research Foundation Biomarqueurs permettant d'évaluer l'exposition à un rayonnement ionisant et la dose absorbée
SG195180A1 (en) 2011-05-31 2013-12-30 Singapore Health Serv Pte Ltd Method for detecting disease biomarkers
EP2730650B1 (fr) * 2011-07-06 2017-01-04 Histocell, S.L. Méthodes de traitement pour des cellules souches mésenchymateuse et leur utilisation pour le traitement des maladies causées par le stress oxydant
GB201116767D0 (en) * 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
RU2667639C2 (ru) 2012-03-21 2018-09-21 Эритек Фарма Лекарственное средство для лечения острого миелоидного лейкоза (омл)
HU230341B1 (hu) * 2012-04-20 2016-02-29 Advancell Diagnosztika Kft. A vörösvérsejt-membrán kvantitatív biomarkerei
WO2014011901A2 (fr) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Procédés et compositions pour la délivrance d'agents biologiques
ES2950419T3 (es) * 2013-05-10 2023-10-09 Erydel Spa Procedimiento para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos obtenidos de esta manera
JP6383920B2 (ja) 2013-09-11 2018-09-05 有限会社ピコデバイス パーキンソン病の判定基準とする方法
EP3130668B1 (fr) * 2014-04-07 2019-07-17 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) Prolifération in vitro de cellules érythroïdes
US11013771B2 (en) * 2015-05-18 2021-05-25 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
CN108700565B (zh) 2015-10-07 2021-10-29 善威生物私人有限公司 血液制备和图谱分析
CN110366597B (zh) 2016-12-20 2024-03-29 善威生物私人有限公司 用蛋白酶抑制剂进行血液图谱分析

Also Published As

Publication number Publication date
JP2018538343A (ja) 2018-12-27
CN108883133A (zh) 2018-11-23
US20190000884A1 (en) 2019-01-03
AU2016374643A1 (en) 2018-07-05
EP3393482A4 (fr) 2019-08-21
EP3393482A2 (fr) 2018-10-31
WO2017106899A3 (fr) 2017-09-28
US11564948B2 (en) 2023-01-31
CA3009369A1 (fr) 2017-06-29
JP2021155454A (ja) 2021-10-07
KR20180102096A (ko) 2018-09-14
AU2016374643B2 (en) 2023-12-14
WO2017106899A2 (fr) 2017-06-29

Similar Documents

Publication Publication Date Title
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201908391XA (en) Methods for modulating an immune response
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201804710TA (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
SG11201809040YA (en) Hybrid aerosol-generating element and method for manufacturing a hybrid aerosol-generating element
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201806453TA (en) Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201408124PA (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201810525XA (en) Anti-gitr antibodies and uses thereof